|
1
|
Coussens LM and Werb Z: Inflammatory cells
and cancer: think different! J Exp Med. 193:23–26. 2001.
|
|
2
|
Yan L, Zucker S and Toole BP: Roles of the
multifunctional glycoprotein, emmprin (basigin; CD 147), in tumour
progression. Thromb Haemost. 93:199–204. 2005.PubMed/NCBI
|
|
3
|
Sheu BC, Hsu SM, Ho HN, Lin RH, Torng PL
and Huang SC: Reversed CD4/CD8 ratios of tumor-infiltrating
lymphocytes are correlated with the progression of human cervical
carcinoma. Cancer. 86:1537–1543. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hayden MS and Ghosh S: Signaling to
NF-kappa B. Genes Dev. 18:2195–2224. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pacifico F and Leonardi A: NF-kB in solid
tumors. Biochem Pharmacol. 72:1142–1152. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sabel MS, Hess SD, Egilmez NK, Conway TF
Jr, Chen FA and Bankert RB: CTLA-4 blockade augments human T
lymphocyte-mediated suppression of lung tumor xenografts in SCID
mice. Cancer Immunol Immunother. 54:944–952. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hori S, Namura T and Sakaguchi S: Control
of regulatory T cell development by the transcription factor Foxp3.
Science. 299:1057–1061. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Maggi E, Cosmi L, Liotta F, Romagnani P,
Romagnani S and Annunziato F: Thymic regulatory T cells. Autoimmun
Rev. 4:579–586. 2005. View Article : Google Scholar
|
|
9
|
Sakaguchi S: Naturally arising CD4+
regulatory cells for immunologic self-tolerance and negative
control of immune responses. Annu Rev Immunol. 22:531–562.
2004.
|
|
10
|
Sato E, Olson SH, Ahn J, Bundy B,
Nishikawa H, Qian F, et al: Intraepithelial CD8+ tumor-infiltrating
lymphocytes and a high CD8+/regulatory T cell ratio are associated
with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA.
102:18538–18543. 2005.
|
|
11
|
de Boer OJ, van der Loos CM, Teeling P,
van der Wal AC and Teunissen MB: Immunohistochemical analysis of
regulatory T cell markers FOXP3 and GITR on CD4+CD25+ T cells in
normal skin and inflammatory dermatoses. J Histochem Cytochem.
55:891–898. 2007.PubMed/NCBI
|
|
12
|
Glick AB, Lee MM, Darwiche N, Kulkarni AB,
Karlsson S and Yuspa SH: Targeted deletion of the TGF-beta 1 gene
causes rapid progression to squamous cell carcinoma. Genes Dev.
8:2429–2440. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Donalisio M, Cornaglia M, Landolfo S and
Lembo D: TGF-β1 and IL-4 downregulate human papillomavirus-16
oncogene expression but have differential effects on the malignant
phenotype of cervical carcinoma cells. Virus Res. 132:253–256.
2008.
|
|
14
|
Massagué J, Blain SW and Lo RS: TGF-beta
signaling in growth control, cancer, and heritable disorders. Cell.
103:295–309. 2000.PubMed/NCBI
|
|
15
|
Moustakas A, Pardali K, Gaal A and Heldin
CH: Mechanisms of TGF-β signaling in regulation of cell growth and
differentiation. Immunol Lett. 82:85–91. 2002.
|
|
16
|
Derynck R, Akhurst RJ and Balmain A:
TGF-beta signaling in tumor suppression. Nat Genet. 29:117–129.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Warnakulasuriya S, Reibel J, Bouquot J and
Dabelsteen E: Oral epithelial dysplasia classification systems:
predictive value, utility, weaknesses and scope for improvement. J
Oral Pathol Med. 37:127–133. 2008. View Article : Google Scholar
|
|
18
|
Piva MR, De Souza LB, Martins-Filho PR,
Soares RC, De Santana Santos T and De Souza Andrade ES: Role of
inflammation in oral carcinogenesis (Part I): Histological grading
of malignancy using a binary system. Oncol Lett. 2:1225–1231.
2011.PubMed/NCBI
|
|
19
|
Abbas NF, Labib El-Sharkawy S, Abbas EA
and Abdel Monem El-Shaer M: Immunohistochemical study of p53 and
angiogenesis in benign and preneoplastic oral lesions and oral
squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol
Oral Endod. 103:385–390. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lind MH, Rozell B, Wallin RP, van
Hogerlinden M, Ljunggren HG, Toftgård R and Sur I: Tumor necrosis
factor receptor 1-mediated signaling is required for skin cancer
development induced by NF-kappaB inhibition. Proc Natl Acad Sci
USA. 101:4972–4977. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jakobsson PA, Eneroth GM, Killander D,
Moberger G and Mårtensson B: Histologic classification and grading
of malignancy in carcinoma of the larynx (a pilot study). Acta
Radiol Ther Phys Biol. 12:1–8. 1973. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bryne M, Koppang HS, Lilleng R, Stene T,
Bang G and Dabelsteen E: New malignancy grading is a better
prognostic indicator than Broders’ grading in oral squamous cell
carcinomas. J Oral Pathol Med. 18:432–437. 1989.PubMed/NCBI
|
|
23
|
Aggarwal BB: Nuclear factor-kappaB: the
enemy within. Cancer Cell. 6:203–208. 2004.PubMed/NCBI
|
|
24
|
Pikarsky E, Porat RM, Stein I, Abramovitch
R, Amit S, Kasem S, et al: NF-kappaB functions as a tumour promoter
in inflammation-associated cancer. Nature. 341:461–466. 2004.
View Article : Google Scholar
|
|
25
|
Aggarwal BB, Shishodia S, Sandur SK,
Pandey MK and Sethi G: Inflammation and cancer: How hot is the
link? Biochem Pharmacol. 72:1605–1621. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gorelik L and Flavell RA: Immune-mediated
eradication of tumors througth the blockade of transforming growth
factor-β signaling in T cells. Nature Med. 7:1118–1122.
2011.PubMed/NCBI
|
|
27
|
Weitzman SA and Gordon LI: Inflammation
and cancer: Role of phagocyte-generated oxidants in carcinogenesis.
Blood. 76:655–663. 1990.PubMed/NCBI
|
|
28
|
Balkwill F and Mantovani A: Inflammation
and cancer: back to Virchow? Lancet. 85:473–483. 2001.
|
